Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression

Steroids

Volumn 78, Issue 6, 2013, Pages 548-554

  Shafi, Ayesha A ^a   Cox, Marc B ^b   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

Androgen receptor (AR); FKBP52; Hsp90; Prostate cancer; Splice variants

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; CHAPERONE; FKBP52 PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG;

CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CONFERENCE PAPER; DRUG TARGETING; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HORMONE ACTION; HORMONE BINDING; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN STABILITY; REGULATORY MECHANISM;

ALTERNATIVE SPLICING; ANIMALS; BENZOQUINONES; HELA CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MICE, KNOCKOUT; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TACROLIMUS BINDING PROTEINS; TUMOR CELLS, CULTURED;

EID: 84876695259     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2012.12.013     Document Type: Conference Paper

References (29)

1. H.V. Heemers, L.J. Schmidt, Z. Sun, K.M. Regan, S.K. Anderson, and K. Duncan Identification of a clinically relevant androgen-dependent gene signature in prostate cancer Cancer Res 71 2011 1978 1988
2. S. Koochekpour Androgen receptor signaling and mutations in prostate cancer Asian J Androl 12 2010 639 657
3. I.U. Agoulnik, and N.L. Weigel Androgen receptor action in hormone-dependent and recurrent prostate cancer J Cell Biochem 99 2006 362 372
4. C.J. Ryan, M.R. Smith, L. Fong, J.E. Rosenberg, P. Kantoff, and F. Raynaud Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J Clin Oncol 28 2010 1481 1488
5. H.I. Scher, K. Fizazi, and F. Saad Effect of MDV3100 an androgen receptor signaling inhibitor (ARSI) on overall survival in patients with prostate cancer postdocetaxel results from the phase III AFFIRM study J Clin Oncol 2012 30 Abstract LBA1-(ASCO Genitourinary Cancers, Symposium Abstracts)
6. E.P. Gelmann Molecular biology of the androgen receptor J Clin Oncol 20 2002 3001 3015
7. J. Ai, Y. Wang, J.A. Dar, J. Liu, L. Liu, and J.B. Nelson HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer Mol Endocrinol 23 2009 1963 1972
8. K.E. Knudsen, and T.M. Penning Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends Endocrinol Metab 21 2010 315 324
9. Y. Chen, C.L. Sawyers, and H.I. Scher Targeting the androgen receptor pathway in prostate cancer Curr Opin Pharmacol 8 2008 440 448
10. Y. Li, M. Alsagabi, D. Fan, G.S. Bova, A.H. Tewfik, and S.M. Dehm Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression Cancer Res 71 2011 2108 2117
11. R. Hu, T.A. Dunn, S. Wei, S. Isharwal, R.W. Veltri, and E. Humphreys Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res 69 2009 16 22
12. S. Sun, C.C. Sprenger, R.L. Vessella, K. Haugk, K. Soriano, and E.A. Mostaghei Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant J Clin Invest 120 2010 2715 2730
13. Z. Guo, X. Yang, F. Sun, R. Jiang, D.E. Linn, and H. Chen A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res 69 2009 2305 2313
14. E. Hörnberg, E.B. Ylitalo, S. Crnalic, H. Antti, P. Stattin, and A. Widmark Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival PLoS ONE 6 2011 e19059
15. Y.S. Kim, S.V. Alarcon, S. Lee, M.J. Lee, G. Giaccone, and L. Neckers Update on Hsp90 inhibitors in clinical trial Curr Top Med Chem 9 2009 1479 1492
16. D.K. Vanaja, S.H. Mitchell, D.O. Toft, and C.Y. Young Effect of geldanamycin on androgen receptor function and stability Cell Stress Chaperones 7 2002 55 64
17. B.L. Conway-Campbell, C.L. George, J.R. Pooley, D.M. Knight, M.R. Norman, and G.L. Hager The HSP90 molecular chaperone cycle regulates cyclical transcriptional dynamics of the glucocorticoid receptor and its coregulatory molecules CBP/p300 during ultradian ligand treatment Mol Endocrinol 25 2011 944 954
18. W. Yong, Z. Yang, S. Periyasamy, H. Chen, S. Yucel, and W. Li Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology J Biol Chem 282 2006 5026 5036
19. J. Cheung-Flynn, V. Prapapanich, M.B. Cox, D.L. Riggs, C. Suarez-Quian, and D.F. Smith Physiological role for the cochaperone FKBP52 in androgen receptor signaling Mol Endocrinol 19 2005 1654 1666
20. J.C. Sivils, C.L. Storer, M.D. Galigniana, and M.B. Cox Regulation of steroid hormone receptor function by the 52-kDaFK506-binding protein (FKBP52) Curr Opin Pharmacol 11 2011 314 319
21. J.T. de Leon, A. Iwai, C. Feau, Y. Garcia, H.A. Balsiger, and C.L. Storer Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells Proc Natl Acad Sci USA 108 2011 11878 11883
22. L.V. Nazareth, and N.L. Weigel Activation of the human androgen receptor through a protein kinase A signaling pathway J Biol Chem 271 1996 19900 19907
23. I.U. Agoulnik, W.C. Krause, W.E.I. Bingman, H.T. Rahman, M. Amrikachi, and G.E. Ayala Repressors of androgen and progesterone receptor action J Biol Chem 278 2003 31136 31148
24. I.U. Agoulnik, A. Vaid, M. Nakka, M. Alvarado, W.E.I. Bingman, and H. Erdem Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer Cancer Res 66 2006 10594 10602
25. S.A. Tomlins, D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, and X.W. Sun Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
26. V.E. Quarmby, W.G. Yarbrough, D.B. Lubahn, F.S. French, and E.M. Wilson Autologous down-regulation of androgen receptor messenger ribonucleic acid Mol Endocrinol 4 1990 22 28
27. X. Zhang, C. Morrissey, S. Sun, M. Ketchandji, P.S. Nelson, and L.D. True Androgen receptor variants occur frequently in castration resistant prostate cancer metastases PLoS ONE 6 2011 e27970
28. A.J. James, I.U. Agoulnik, J.M. Harris, G. Buchanan, W.D. Tilley, and M. Marcelli A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity Mol Endocrinol 16 2002 2692 2705
29. A.J. Saporita, J. Ai, and Z. Wang The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells Prostate 67 2007 509 520